Literature DB >> 12756408

Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region.

B Strauch1, T Zelinka, M Hampf, R Bernhardt, J Widimsky.   

Abstract

Recently published studies from different parts of the world report significantly higher prevalence of primary hyperaldosteronism (PH) in hypertensives (ranging from 5 to 25%) than the previously accepted figures. There have been no data so far about the prevalence of PH in Central Europe. Therefore, we have undertaken this study to evaluate the prevalence of PH in patients with moderate to severe hypertension referred to a hypertension unit in the Czech Republic, together with the determination of the percentage of different subtypes of PH including familial forms. In addition to that, we have evaluated the prevalence of other types of secondary forms of hypertension.A total of 402 consecutive patients (230 females and 172 males) with hypertension, referred to our hypertension unit, were studied. Positive aldosterone/renin ratio (ARR, (ng/100 ml)/(ng/ml/h)) >/=50 as a more strict marker of PH was found in 87 patients (21.6%), 30% of them were normokalaemic. The diagnosis of PH was later confirmed in 77 cases (89%); the total prevalence of PH was thus 19%. PH consisted of the following forms: idiopathic hyperaldosteronism 42%, unilateral aldosterone-producing adenoma 36%, unilateral hyperplasia 7%, nonclassifiable PH (refused operation/adrenal venous sampling) 13%, familial hyperaldosteronism type 1.2%. The prevalence of other types of secondary hypertension was as follows: pheochromocytoma 5%, renovascular 4.5%, hypercortisolism 2%, renal 0.75%. In conclusion, we have noted that PH in the Central Europe region (Czech Republic) is the most frequent form of endocrine hypertension with a considerably high prevalence in moderate to severe hypertension. Application of more strict criteria raises the probability of correct diagnosis of PH including the early normokalaemic stages of PH.

Entities:  

Mesh:

Year:  2003        PMID: 12756408     DOI: 10.1038/sj.jhh.1001554

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  54 in total

1.  Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.

Authors:  Carolina C Gonzaga; Krishna K Gaddam; Mustafa I Ahmed; Eduardo Pimenta; S Justin Thomas; Susan M Harding; Suzanne Oparil; Stacey S Cofield; David A Calhoun
Journal:  J Clin Sleep Med       Date:  2010-08-15       Impact factor: 4.062

2.  Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension.

Authors:  O Petrák; T Zelinka; B Štrauch; J Rosa; Z Šomlóová; T Indra; H Turková; R Holaj; J Widimský
Journal:  J Hum Hypertens       Date:  2015-04-02       Impact factor: 3.012

Review 3.  Resistant hypertension and aldosteronism.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

Review 4.  Primary aldosteronism: a common cause of resistant hypertension.

Authors:  Gregory A Kline; Ally P H Prebtani; Alexander A Leung; Ernesto L Schiffrin
Journal:  CMAJ       Date:  2017-06-05       Impact factor: 8.262

Review 5.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

6.  The role of aldosteronism in causing obesity-related cardiovascular risk.

Authors:  David A Calhoun; Kumar Sharma
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

Review 7.  Resistant hypertension and hyperaldosteronism.

Authors:  Carolina C Gonzaga; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 8.  Primary Aldosteronism: Practical Approach to Diagnosis and Management.

Authors:  James Brian Byrd; Adina F Turcu; Richard J Auchus
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

9.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

10.  Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.

Authors:  K Gaddam; E Pimenta; S J Thomas; S S Cofield; S Oparil; S M Harding; D A Calhoun
Journal:  J Hum Hypertens       Date:  2009-12-17       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.